Spots Global Cancer Trial Database for 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

Official Title: An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC

Study ID: NCT03001349

Conditions

Meningioma

Metastatic Well Differentiated Neuroendocrine Neoplasm

Multiple Endocrine Neoplasia Type 1

Neuroendocrine Neoplasm

Somatostatin Positive Neoplastic Cells Present

Von Hippel-Lindau Syndrome

Interventions

Computed Tomography

Gallium Ga 68-Edotreotide

Positron Emission Tomography

Study Description

Brief Summary: This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic procedures, such as 68Ga-DOTA-TOC PET/CT, may help find and diagnose neuroendocrine tumors.

Detailed Description: PRIMARY OBJECTIVES: I. To substitute 68Ga-DOTATOC for 111In-pentetreotide on an expanded access basis, in tumor imaging for study subjects, where the care provider believes that somatostatin imaging is clinically indicated, until such time as 68Ga-DOTATOC becomes commercially available. SECONDARY OBJECTIVES: I. To gain experience in the utility of 68Ga-DOTATOC in the management of neuroendocrine tumors at The University of Texas M.D. Anderson Cancer Center (MDACC). II. To acquire proficiency in generating 68Ga-DOTATOC for human use at MDACC. OUTLINE: Participants receive gallium Ga 68-edotreotide intravenously. After 1 hour, participants undergo PET/CT scan over 60 minutes. After completion of study, participants are followed up at 24 hours or within 72 hours, and at 30 days.